A new semisynthetic penicillinase-resistant penicillin, cloxacillin, was used in treatment of 100 hospitalized patients with severe infections. Twenty-three of 25 patients with staphylococcal infections, 30 of 37 with pneumococcal infections, all 13 patients with streptococcal infection, and 17 of 25 with infection due to a variety of organisms responded favorably. At the present time, the drug is available only in oral-dosage form, limiting its use in severely ill patients. A toxic effect on the gastrointestinal tract was not observed; rashes developed in two patients. Serious superinfections occurred in at least three patients with pneumococcal pneumonia. Cloxacillin compares favorably with other semisynthetic penicillinaseresistant penicillins now available in the oral-dosage form.
Turck M, Ronald A, Petersdorf RG. Clinical Studies With CloxacillinA New Antibiotic. JAMA. 1965;192(11):961–963. doi:10.1001/jama.1965.03080240031006
Customize your JAMA Network experience by selecting one or more topics from the list below.